Q2
CSTL — Q2 2026 Financial Report Analysis
Castle Biosciences' Q2 2026 revenue rose 20.1% to $103.5M as TissueCypher reports jumped 63%, offsetting a Medicare-driven slide in its SCC skin-cancer test; it posted a $2.1M net loss and raised 2026 revenue guidance to $365-375M.